Accurate patient selection and multimodal treatment offer the best therapeutic option in high-risk prostate cancer

Abstract

High-risk prostate cancer (HRPC) has higher recurrence potential and multimodal treatment offers better outcomes in this population. The aim of this article is to comprehensively present the multimodal therapeutic options for HRPC. Review of the literature on HRPC with a literature selection based on evidence and practical considerations. Therapeutic options for localized HRPC are radio hormone therapy and radical prostatectomy with extended lymph node dissection. Selection of patients is essential to define individualized therapeutic strategy and timing for every modality should come as a consensus of medical supported evidence. Accurate patient selection and multimodal treatment offer the best therapeutic option in HRPC.

Keywords::

• androgen deprivation
• biochemical recurrence
• high risk
• multimodal
• prostate cancer
• radical prostatectomy
• radiotherapy
• survival

Financial & competing interests disclosure

All authors have made a significant contribution to the findings and methods in the paper. All authors have read and approved the final draft. This work has not already been published and has not been submitted simultaneously to any other journal. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.